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Malignant Hyperthermia
Kathryn Hernandez BSN, RN, CCRN, SRNA
Overview
q The rare genetic condition of malignant hyperthermia (MH) is widely 
researched by anesthesia providers. 
q MH is a condition in which the body goes into a hypermetabolic state 
affecting skeletal muscle in response to receiving inhaled anesthetics or the 
neuromuscular blocking agent, succinylcholine. Early recognition and 
treatment is necessary as this condition is fatal if left untreated.
q The exact incidence of MH is not well understood. MH presents in about 1 in 
100,000 adult surgeries ; and 1 in about 30,000 pediatric surgeries.
q MH research allows for a more thorough understanding of the condition: the 
causes, clinical presentation, and most importantly how to treat the 
condition to prevent fatalities. 
(Malignant Hyperthermia Association of the United States, 2020; Rosenberg et al., 
2015). 
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Diagnosis
Treatment                     Conclusion & 
Significance
q With the complexity of this disorder and 
its unique pathophysiological process it is 
crucial that all parts of the surgical team, 
especially anesthesia providers, 
understand how to treat a patient with 
MH.
q Certified registered nurse anesthetists 
(CRNA) are responsible for monitoring 
patients very closely. Clinical signs of MH 
must be recognized and treated early in 
order to decrease morbidity and mortality. 
q Increased understanding of the clinical 
manifestation and pathophysiology of MH 
has led to a decrease in mortality from 
80% thirty years ago to <5% in 2006.




q MH results in a hypermetabolic state causing the following signs 
and symptoms:
• Hyperthermia





-Occurs immediately after administration of anesthetic agent or 
succinylcholine
• Rhabdomyolysis
- Dark color urine, marked increase in CPK levels
• Hypercapnia





-Can lead to dysrhythmias   
(DeWel, B., & Claeys, K.G., 2018)
q MH is an autosomal dominant disorder that is 
most closely related to a mutation in the 
ryanodine receptor type 1 (RyR1) gene. 
• Additional genetic mutations 
associated with MH include: 
CACNA1S
q Following the administration of triggering 
agents such as inhaled anesthetics or 
succinylcholine, the defective receptor (RyR1) 
causes an uncontrolled release of calcium from 
the sarcoplasmic reticulum.
q Increased intracellular calcium facilitates 
excessive excitation-coupling leading to 
inappropriate muscle contraction and a deadly 
hypermetabolic state. 
(Rosenberg et al., 2015; Stephens et al., 2016)
q Prior history of MH
q Musculoskeletal disorder
q History of rhabdomyolysis
q Greater incidence in males
q Highest incidence in young people, with average age of 18.3 
years
q If parent has defect RyR1 gene, 50% chance of passing it to 
offspring (autosomal dominant)
(Rosenberg et al., 2015; Stephens et al., 2016)
(AANA, 2020)
q Based on clinical presentation/ lab testing:
• Elevated temperature: >38.8 increasing 1 degree every 5 minutes
• Elevated EtC02 >55mmHg despite increased minute ventilation
• Muscle rigidity 
• Rhabdomyolysis: elevated creatine kinase, cola-colored urine, 
elevated myoglobin 
• Blood/plasma/serum K+> 6 mEq/L
q The “gold standard” for diagnosis of MH is an in vitro contracture 
test.
• Based on contracture of muscle fibers in the presence of 
halothane or caffeine
(Rosenberg et al., 2015)
(Rosenberg et al., 2015)
q Immediate discontinuation of trigger agents
q Dantrolene 2.5mg/kg q 10-15 min till resolution of 
symptoms
• Works by directly decreasing calcium in the cell and 
interferes with muscle contraction
• Only drug that specifically treats MH
q Supportive Care
• Temperature cooling measures
• Increase minute ventilation
• Traditional hyperkalemia management
(Malignant Hyperthermia Association of the United States, 
2020; Rosenberg et al., 2015)
Medical interventions:
q Administration of dantrolene




q Understand and monitor for early signs and symptoms of MH
q Assess for susceptibilities of MH and past medical history
q Collect and monitor lab results
(AANA, 2020; Malignant Hyperthermia Association of the United States, 2020; 
Rosenberg et al., 2015)




Diagnostic Grading Scale 
(Norgine, 2016)
